Journal article

Publication year: 1997

Pages: 2042-2047

Journal: Blood

Volume number: 89

Issue number: 6

ISSN: 0006-4971

DOI Link: https://doi.org/10.1182/blood.V89.6.2042

Publisher: American Society of Hematology (ASH Publications)

Abstract: 

Fifteen patients with refractory Hodgkin's disease were treated in a phase I/II trial with the natural killer (NK)-cell-activating bispecific monoclonal antibody HRS-3/A9, which is directed against the Fc gamma-receptor III (CD16 antigen) and the Hodgkin's-associated CD30 antigen, respectively, Median counts of NK cells and of all lymphocyte subsets were considerably decreased in the patients before therapy, HRS-3/A9 was administered 4 times every 3 to 4 days, starting with 1 mg/m(2), The treatment was well tolerated, and the maximum tolerated dose was not reached at 64 mg/m(2), the highest dose administered because of the limited amounts of HRS-3/A9 available. Side effects were rare and consisted of fever, pain in involved lymph nodes, and a maculopapulous rash, A total of 9 patients developed human antimouse Ig antibodies, and 4 patients developed an allergic reaction after attempted retreatment. A total of 1 complete and 1 partial remission (lasting 16 and 3 months, respectively), 3 minor responses (1 to 11+ months), and 1 mixed response were achieved. There was no clear-cut dose-side effect or dose-response correlation, Our results encourage further clinical trials with this novel immunotherapeutic approach and emphasize the necessity to reduce the immunogenicity of the murine bispecific antibodies.

Harvard Citation style: Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., et al. (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody, Blood, 89(6), pp. 2042-2047. https://doi.org/10.1182/blood.V89.6.2042

APA Citation style: Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., & Pfreundschuh, M. (1997). Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood. 89(6), 2042-2047. https://doi.org/10.1182/blood.V89.6.2042